Pexastimogene devacirepvec

Drug Profile

Pexastimogene devacirepvec

Alternative Names: JX-594; Pexa-Vec; TG-6006

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jennerex Biotherapeutics
  • Developer Green Cross; Jennerex; National Cancer Institute (France); SillaJen Biotherapeutics; Transgene
  • Class Antineoplastics; Gene therapies; Granulocyte-macrophage colony-stimulating factors; Oncolytic viruses
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hepatocellular carcinoma
  • Phase II Breast cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours
  • Phase I/II Malignant melanoma
  • Phase I Colorectal cancer
  • Preclinical Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 13 Sep 2017 Phase-II clinical trials in Hepatocellular carcinoma (Combination therapy, First-line therapy, Late-stage disease) in France (IV) (NCT03071094)
  • 16 Aug 2017 SillaJen announces CRADA with the National Cancer Institute (NCI) for the development of pexastimogene devacirepvec (Pexa-Vec) colorectal cancer
  • 21 Jul 2017 China FDA approves an IND application for initiation of the phase III PHOCUS trial in Hepatocellular carcinoma (Late-stage disease, First-line therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top